United States · FDA National Drug Code directory
Terazosin
A source-listed medicine record.
Factual source checks only. This page is not a clinically reviewed monograph. Historical or discontinued records may be included; listing does not confirm approval, current availability or pharmacy stock.
Medicine identity
- Source reference
- 71610-510_b23a32b3-7e6b-4b58-be96-303ac3ef069a
- Product NDC
- 71610-510
- Form
- CAPSULE
- Composition / generic term
- Terazosin Hydrochloride
- Labeler
- Aphena Pharma Solutions - Tennessee, LLC
- Marketing category
- ANDA
- Marketing start / end (source format)
- 20200330
- Source listing expiry
- 20261231
Source-listed ingredients
- TERAZOSIN HYDROCHLORIDE — 2 mg/1
These values do not establish equivalence or a dose recommendation.
Packages
- 30 CAPSULE in 1 BOTTLE (71610-510-30) · 71610-510-30
- 60 CAPSULE in 1 BOTTLE (71610-510-53) · 71610-510-53
- 90 CAPSULE in 1 BOTTLE (71610-510-60) · 71610-510-60
- 120 CAPSULE in 1 BOTTLE (71610-510-70) · 71610-510-70
- 180 CAPSULE in 1 BOTTLE (71610-510-80) · 71610-510-80
- 270 CAPSULE in 1 BOTTLE (71610-510-92) · 71610-510-92
- 360 CAPSULE in 1 BOTTLE (71610-510-94) · 71610-510-94
Source and coverage
Open FDA National Drug Code directory →
Snapshot retrieved: 2026-09-17. This is the acquisition date, not a medical review date.
Clinical information, images and comparisons appear only when separately reviewed for this record. Coverage may be incomplete. Ask a pharmacist or clinician about your treatment.
Browse United States records →